Back to Trades
Sell4
Rapport Therapeutics, Inc.
RAPP
Total Value
$268.3K
Net $246.7K sold
Sales
$246.7K
3 transactions
Company Information
- Company Name
- Rapport Therapeutics, Inc.
- Ticker Symbol
- RAPP
- CIK
- 0002012593
Insider Information
- Name
- Bredt David
- Role
- Insider
- Location
- BOSTON, MA
Filing Details
- Filing Date
- Feb 19, 2026
- Transaction Date
- Feb 17, 2026
- Accession Number
- 0001193125-26-059883
- Form Type
- 4
- Net Trading Amount
- -$246.7K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Feb 17, 2026 | Common Stock | 900 | $28.02 | Sale | $25.2K |
| Feb 17, 2026 | Common Stock | 5,400 | $28.95 | Sale | $156.3K |
| Feb 17, 2026 | Common Stock | 2,200 | $29.59 | Sale | $65.1K |
| Feb 19, 2026 | Common Stock | 6,000 | $1.80 | Exercise | $10.8K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 19, 2026 | Derivative | 6,000 | $1.80 | Exercise | $10.8K |
Footnotes
- (F1)These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
- (F2)The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- (F3)The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- (F4)The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- (F5)Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction.
- (F6)25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.